Aliqopa (copanlisib)

News alerts, weekly reports and conference planners

Company:

Bayer

Drug class:

PIK3CA inhibitor, PI3Kδ inhibitor

Related drugs:

‹

›

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B
CD20 positive	Lymphoma	CD20 positive	Lymphoma	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B	rituximab + copanlisib Sensitive: B - Late Trials rituximab + copanlisib Sensitive : B
PIK3CA mutation	Uterine Cancer	PIK3CA mutation	Uterine Cancer	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + copanlisib Sensitive: C2 – Inclusion Criteria trastuzumab + copanlisib Sensitive : C2	trastuzumab + copanlisib Sensitive: C2 – Inclusion Criteria trastuzumab + copanlisib Sensitive : C2
CD20 positive	Lymphoma	CD20 positive	Lymphoma	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
RHOA mutation	Peripheral T-cell Lymphoma	RHOA mutation	Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
IDH2 mutation	Peripheral T-cell Lymphoma	IDH2 mutation	Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
TSC2 mutation	Peripheral T-cell Lymphoma	TSC2 mutation	Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
PIK3CA mutation	Liposarcoma	PIK3CA mutation	Liposarcoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
PIK3CA mutation + PTEN deletion	Solid Tumor	PIK3CA mutation + PTEN deletion	Solid Tumor	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3
FANCA mutation	Prostate Cancer	FANCA mutation	Prostate Cancer	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3	rucaparib + copanlisib Sensitive: C3 – Early Trials rucaparib + copanlisib Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib + copanlisib Sensitive: C3 – Early Trials abemaciclib + copanlisib Sensitive : C3	abemaciclib + copanlisib Sensitive: C3 – Early Trials abemaciclib + copanlisib Sensitive : C3
PTEN deletion + BCL2 translocation	Diffuse Large B Cell Lymphoma	PTEN deletion + BCL2 translocation	Diffuse Large B Cell Lymphoma	venetoclax + copanlisib Sensitive: D – Preclinical venetoclax + copanlisib Sensitive : D	venetoclax + copanlisib Sensitive: D – Preclinical venetoclax + copanlisib Sensitive : D
PIK3CG expression	Mantle Cell Lymphoma	PIK3CG expression	Mantle Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
PIK3CG expression	Mantle Cell Lymphoma	PIK3CG expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CD expression	Mantle Cell Lymphoma	PIK3CD expression	Mantle Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
PIK3CD expression	Mantle Cell Lymphoma	PIK3CD expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CB expression	Mantle Cell Lymphoma	PIK3CB expression	Mantle Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
PIK3CB expression	Mantle Cell Lymphoma	PIK3CB expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CA expression	Mantle Cell Lymphoma	PIK3CA expression	Mantle Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
PIK3CA expression	Mantle Cell Lymphoma	PIK3CA expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CA mutation	Cervical Cancer	PIK3CA mutation	Cervical Cancer	neratinib + copanlisib Sensitive: D – Preclinical neratinib + copanlisib Sensitive : D	neratinib + copanlisib Sensitive: D – Preclinical neratinib + copanlisib Sensitive : D
BCL2 rearrangement + MYC amplification	Diffuse Large B Cell Lymphoma	BCL2 rearrangement + MYC amplification	Diffuse Large B Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D
PTEN underexpression	Prostate Cancer	PTEN underexpression	Prostate Cancer	copanlisib + darolutamide Sensitive: D – Preclinical copanlisib + darolutamide Sensitive : D	copanlisib + darolutamide Sensitive: D – Preclinical copanlisib + darolutamide Sensitive : D
PTPN11 mutation + KRAS wild-type	Non Small Cell Lung Cancer	PTPN11 mutation + KRAS wild-type	Non Small Cell Lung Cancer	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D	copanlisib Sensitive: D – Preclinical copanlisib Sensitive : D

Aliqopa (copanlisib)

Associations
(32)

Associations
(32)

Aliqopa (copanlisib)

Associations(32)

Associations(32)

Associations
(32)

Associations
(32)